Please ensure Javascript is enabled for purposes of website accessibility

Why Inogen Shares Are Plunging Today

By Brian Feroldi – Updated May 8, 2019 at 12:23PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The stock sinks after the medical device marker slashes its full-year guidance.

What happened

In response to reporting first-quarter results and lowering its guidance, shares of Inogen (INGN 4.97%), a high-growth medical device company focused on oxygen therapy, fell 24% as of 11:40 a.m. EDT on Wednesday.

So what

Here are the headline numbers from the quarter: 

  • Revenue grew 14% to $90.2 million. That beat the $89.6 million that Wall Street was expecting.
  • Gross margin rose 150 basis points to 49.2%.
  • Operating expenses rose 36% to $39.6 million. The big jump was caused by increased employee head count and higher advertising expenses.
  • Net income was cut in half to $5.3 million, or $0.24 per share. That was below the $0.30 that analysts were expecting.

The mixed quarterly results weren't great, but the huge contraction in the share price appears to be related to management's full-year guidance updates:

  • Total revenue is expected to land between $405 million and $415 million. That's down from its prior range of $430 million to $440 million.
  • Operating income is expected to land between $42 million and $44 million, down from $46 million to $50 million.
  • Adjusted EBITDA is expected to land between $66 million and $68 million, down from $67 million to $71 million.
  • Net income is now expected to land between $36 million and $38 million. That's down from its prior range of $40 million to $44 million. It's also a steep decline from last year's net income of $51.8 million.
  • Free cash flow is expected to remain positive for the full year but will be lower than in 2018.

On the conference call with investors, CEO Scott Wilkinson stated that the company's domestic business-to-business sales are facing challenges that are pressuring near-term growth. The company is also shifting its business toward a rental model, which acts as a near-term headwind on revenue and profits. 

Man with head against wall in conference room

Image source: Getty Images.

Check out the latest Inogenearnings call transcript.

Now what

The good news for investors is that Inogen still expects to post double-digit top-line growth in 2019. The bad news is that the bottom line is expected to contract significantly. If management can get net income growth back on track in 2020, then today's drop could represent a nice buying opportunity for investors who have been waiting for their chance to get in. 

Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inogen, Inc. Stock Quote
Inogen, Inc.
INGN
$23.87 (4.97%) $1.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.